Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label Study to Characterize Single and Repeat Dose Pharmacokinetics (Including Food Effect) of Tebipenem-pivoxil-hydrobromide and Its Major Metabolite (SPR1349) in Healthy Participants
Conditions
Interventions
TBP-PI-HBr
Locations
1
United States
Medical Facility, Salt Lake City
Salt Lake City, Utah, United States
Start Date
November 20, 2024
Primary Completion Date
April 22, 2025
Completion Date
April 22, 2025
Last Updated
May 20, 2025
NCT06342713
NCT07310901
NCT07401472
NCT07412353
NCT07280858
NCT07300189
Lead Sponsor
Spero Therapeutics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions